Sampath Anand
EVP, Operations
Sampath Anand has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 12, 2026.
On the most recent filing, Sampath Anand is listed as EVP, Ops & Clinical Research at MASIMO CORP. Inside the rolling window, Sampath Anand reported no open-market purchases and 1 open-market sale totaling $2.6M in MASI.
Companies traded
Other insiders at MASI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.6M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Sampath Anand made?
Sampath Anand has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Sampath Anand trade?
Sampath Anand has filed SEC Form 4 disclosures for 1 company, including MASI.
When was Sampath Anand's most recent SEC Form 4 filing?
Sampath Anand's most recent SEC Form 4 filing on Tracefour is dated Jun 12, 2026.
What is Sampath Anand's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Sampath Anand is listed as EVP, Operations.
What is Sampath Anand's total buy and sell value in the current window?
Inside the rolling retention window, Sampath Anand bought $0 and sold $2.6M based on SEC Form 4 filings.
What was Sampath Anand's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 18,680 MASI shares on 2026-01-28, worth $2.6M, per SEC Form 4 filings.